Rectal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Rectal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rectal Cancer - Drugs In Development, 2022, provides an overview of the Rectal Cancer (Oncology) pipeline landscape.

Rectal cancer affects the lower part of the colon, which connects the large bowel to the anus. The risk factors for developing rectal cancer are increasing age, smoking, family history of colon or rectal cancer, high-fat diet and/or a diet mostly from animal sources and personal or family history of polyps or colorectal cancer. Rectal cancer commonly spreads to organs such as the liver and the lungs. The common signs and symptoms of rectal cancer include a change in bowel habits, diarrhea, constipation, or feeling that the bowel does not empty completely, blood, either bright red or very dark in the stool, stools that are narrower than usual, general abdominal discomfort such as frequent gas pains, bloating, fullness or cramps, weight loss with no known reason, constant tiredness and vomiting. Rectal cancer treatment includes surgery, radiation therapy or chemotherapy, or a combination of these approaches

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rectal Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Rectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Rectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 19, 25, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Rectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rectal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Rectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rectal Cancer (Oncology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rectal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Rectal Cancer – Overview
Rectal Cancer – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Rectal Cancer – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Rectal Cancer – Companies Involved in Therapeutics Development
Advaxis Inc
Alkermes Plc
Amphivena Therapeutics Inc
Apexigen Inc
AptaBio Therapeutics Inc
Arcus Biosciences Inc
AstraZeneca Plc
BeiGene Ltd
Beijing Konruns Pharmaceutical Co Ltd
BioAtla Inc
Biomimetix JV LLC
Bristol-Myers Squibb Co
CytomX Therapeutics Inc
Diverse Biotech Inc
Eisai Co Ltd
Eli Lilly and Co
Ellipses Pharma Ltd
F. Hoffmann-La Roche Ltd
Genentech USA Inc
Genexine Inc
Genome & Co
GlaxoSmithKline Plc
Harbin Gloria Pharmaceuticals Co Ltd
Hutchison MediPharma Ltd
Incyte Corp
Innovent Biologics Inc
Jiangsu Hengrui Medicine Co Ltd
LipoMedix Pharmaceutical Inc
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Novartis AG
Oncolys BioPharma Inc
OncXerna Therapeutics Inc
Ono Pharmaceutical Co Ltd
Pieris Pharmaceuticals Inc
Precigen Inc
Privo Technologies Inc
Sanofi
Shanghai Haihe Biopharma Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
SQZ Biotechnologies Co
Taiho Oncology Inc
Teon Therapeutics Inc
Rectal Cancer – Drug Profiles
(tipiracil hydrochloride + trifluridine) – Drug Profile
AMV-564 – Drug Profile
Aptamer for Colon Cancer and Rectal Cancer – Drug Profile
atezolizumab – Drug Profile
axalimogene filolisbac – Drug Profile
bavituximab – Drug Profile
bintrafusp alfa – Drug Profile
BMX-001 – Drug Profile
camrelizumab – Drug Profile
cannabidiol – Drug Profile
Cellular Immunotherapy for Oncology – Drug Profile
cinrebafusp alfa – Drug Profile
cisplatin – Drug Profile
CX-1026 – Drug Profile
dostarlimab – Drug Profile
durvalumab – Drug Profile
E-7130 – Drug Profile
efineptakin alfa – Drug Profile
epacadostat – Drug Profile
etrumadenant – Drug Profile
fruquintinib – Drug Profile
galunisertib monohydrate – Drug Profile
GEN-001 – Drug Profile
ipilimumab + nivolumab – Drug Profile
LPMX-1 – Drug Profile
LTT-462 – Drug Profile
M-9241 – Drug Profile
MK-8353 – Drug Profile
naporafenibum – Drug Profile
nemvaleukin alfa – Drug Profile
niraparib – Drug Profile
NLG-207 – Drug Profile
OBP-702 – Drug Profile
Oncology – Drug Profile
Oncology 1 – Drug Profile
ONO-4578 – Drug Profile
ozuriftamab vedotin – Drug Profile
pacmilimab – Drug Profile
palupiprant – Drug Profile
PRGN-2009 – Drug Profile
SAR-442720 – Drug Profile
SHR-1701 – Drug Profile
simmitecan hydrochloride – Drug Profile
simurosertib – Drug Profile
sintilimab – Drug Profile
sotigalimab – Drug Profile
tiragolumab – Drug Profile
tislelizumab – Drug Profile
TT-038 – Drug Profile
tucidinostat – Drug Profile
zimberelimab – Drug Profile
Rectal Cancer – Dormant Projects
Rectal Cancer – Discontinued Products
Rectal Cancer – Product Development Milestones
Featured News & Press Releases
Nov 12, 2021: Apexigen announces new phase 2 clinical data on CD40 antibody sotigalimab at the SITC 2021 Annual Meeting
Feb 04, 2021: National Comprehensive Cancer Network provides updates on use of LONSURF (trifluridine and tipiracil) in NCCN Drugs and Biologics Compendium for colon cancer and rectal cancer
Oct 22, 2018: NCCN awarded $2 million in research funding from Taiho Oncology to study Trifluridine and Tipiracil in various cancers
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Rectal Cancer, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
Table 5: Number of Products under Development by Universities/Institutes, 2022
Table 6: Products under Development by Companies, 2022
Table 7: Products under Development by Companies, 2022 (Contd..1)
Table 8: Products under Development by Companies, 2022 (Contd..2)
Table 9: Products under Development by Universities/Institutes, 2022
Table 10: Number of Products by Stage and Target, 2022
Table 11: Number of Products by Stage and Target, 2022 (Contd..1)
Table 12: Number of Products by Stage and Mechanism of Action, 2022
Table 13: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Table 14: Number of Products by Stage and Route of Administration, 2022
Table 15: Number of Products by Stage and Molecule Type, 2022
Table 16: Rectal Cancer – Pipeline by Advaxis Inc, 2022
Table 17: Rectal Cancer – Pipeline by Alkermes Plc, 2022
Table 18: Rectal Cancer – Pipeline by Amphivena Therapeutics Inc, 2022
Table 19: Rectal Cancer – Pipeline by Apexigen Inc, 2022
Table 20: Rectal Cancer – Pipeline by AptaBio Therapeutics Inc, 2022
Table 21: Rectal Cancer – Pipeline by Arcus Biosciences Inc, 2022
Table 22: Rectal Cancer – Pipeline by AstraZeneca Plc, 2022
Table 23: Rectal Cancer – Pipeline by BeiGene Ltd, 2022
Table 24: Rectal Cancer – Pipeline by Beijing Konruns Pharmaceutical Co Ltd, 2022
Table 25: Rectal Cancer – Pipeline by BioAtla Inc, 2022
Table 26: Rectal Cancer – Pipeline by Biomimetix JV LLC, 2022
Table 27: Rectal Cancer – Pipeline by Bristol-Myers Squibb Co, 2022
Table 28: Rectal Cancer – Pipeline by CytomX Therapeutics Inc, 2022
Table 29: Rectal Cancer – Pipeline by Diverse Biotech Inc, 2022
Table 30: Rectal Cancer – Pipeline by Eisai Co Ltd, 2022
Table 31: Rectal Cancer – Pipeline by Eli Lilly and Co, 2022
Table 32: Rectal Cancer – Pipeline by Ellipses Pharma Ltd, 2022
Table 33: Rectal Cancer – Pipeline by F. Hoffmann-La Roche Ltd, 2022
Table 34: Rectal Cancer – Pipeline by Genentech USA Inc, 2022
Table 35: Rectal Cancer – Pipeline by Genexine Inc, 2022
Table 36: Rectal Cancer – Pipeline by Genome & Co, 2022
Table 37: Rectal Cancer – Pipeline by GlaxoSmithKline Plc, 2022
Table 38: Rectal Cancer – Pipeline by Harbin Gloria Pharmaceuticals Co Ltd, 2022
Table 39: Rectal Cancer – Pipeline by Hutchison MediPharma Ltd, 2022
Table 40: Rectal Cancer – Pipeline by Incyte Corp, 2022
Table 41: Rectal Cancer – Pipeline by Innovent Biologics Inc, 2022
Table 42: Rectal Cancer – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Table 43: Rectal Cancer – Pipeline by LipoMedix Pharmaceutical Inc, 2022
Table 44: Rectal Cancer – Pipeline by Merck & Co Inc, 2022
Table 45: Rectal Cancer – Pipeline by Merck KGaA, 2022
Table 46: Rectal Cancer – Pipeline by Millennium Pharmaceuticals Inc, 2022
Table 47: Rectal Cancer – Pipeline by Novartis AG, 2022
Table 48: Rectal Cancer – Pipeline by Oncolys BioPharma Inc, 2022
Table 49: Rectal Cancer – Pipeline by OncXerna Therapeutics Inc, 2022
Table 50: Rectal Cancer – Pipeline by Ono Pharmaceutical Co Ltd, 2022
Table 51: Rectal Cancer – Pipeline by Pieris Pharmaceuticals Inc, 2022
Table 52: Rectal Cancer – Pipeline by Precigen Inc, 2022
Table 53: Rectal Cancer – Pipeline by Privo Technologies Inc, 2022
Table 54: Rectal Cancer – Pipeline by Sanofi, 2022
Table 55: Rectal Cancer – Pipeline by Shanghai Haihe Biopharma Co Ltd, 2022
Table 56: Rectal Cancer – Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022
Table 57: Rectal Cancer – Pipeline by SQZ Biotechnologies Co, 2022
Table 58: Rectal Cancer – Pipeline by Taiho Oncology Inc, 2022
Table 59: Rectal Cancer – Pipeline by Teon Therapeutics Inc, 2022
Table 60: Rectal Cancer – Dormant Projects, 2022
Table 61: Rectal Cancer – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Rectal Cancer, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products by Top 10 Targets, 2022
Figure 4: Number of Products by Stage and Top 10 Targets, 2022
Figure 5: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Top 10 Routes of Administration, 2022
Figure 8: Number of Products by Stage and Top 10 Routes of Administration, 2022
Figure 9: Number of Products by Top 10 Molecule Types, 2022
Figure 10: Number of Products by Stage and Top 10 Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings